Two years of treatment with oral Gilenya (fingolimod) significantly reduced the rate of relapses when compared to Avonex (interferon beta-1a) intramuscular injections in children and adolescents with relapsing forms of multiple sclerosis (RMS), according to Phase 3 clinical trial results.
Additionally, Gilenya (marketed by Novartis) decreased the number of central nervous system (CNS) lesions as observed with magnetic resonance imaging (MRI) over the same period.
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
To receive MS news and information via e-mail, Please Click here
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
No comments:
Post a Comment
Thank You for leaving a comment.
Attempts to redirect viewers of this blog to another website and / or any marketing, will be removed.
Note: Only a member of this blog may post a comment.